Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 6;109(19):3045-3047.
doi: 10.1016/j.neuron.2021.09.007. Epub 2021 Sep 27.

Aducanumab and the "post-amyloid" era of Alzheimer research?

Erik S Musiek  1 , David A Bennett  2
Affiliations

Aducanumab and the "post-amyloid" era of Alzheimer research?

Erik S Musiek et al. Neuron. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of interests Dr. Musiek has provided consultation and has received research funding from Eisai Pharmaceuticals, the co-developer of aducanumab and developer of lecanemab. This interaction with Eisai is related to basic sleep research and is unrelated to aducanumab, lecanemab, or any other amyloid antibodies. No personal compensation was provided. Dr. Bennett has consulted for Takeda, Abbvie, Origent, and Vigorous Minds. He has received research funding from Biogen, the developer of aducanumab, for data analysis of data generated from his own group, and from Neurovision.

References

    1. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, and Wilson RS (2006). Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837–1844. - PubMed
    1. Boyle PA, Yu L, Leurgans SE, Wilson RS, Brookmeyer R, Schneider JA, and Bennett DA (2019). Attributable risk of Alzheimer’s dementia attributed to age-related neuropathologies. Annals of neurology 85, 114–124. - PMC - PubMed
    1. Boyle PA, Yu L, Wilson RS, Leurgans SE, Schneider JA, and Bennett DA (2018). Person-specific contribution of neuropathologies to cognitive loss in old age. Annals of neurology 83, 74–83. - PMC - PubMed
    1. Haeberlein SB, von Hehn C, Chalkias S, Muralidharan KK, Chen T, Wu SY, Li J, Skordos L, Nisenbaum L, Rajagovindan R, et al. (2019). EMERGE and ENGAGE Topline Results: Two Phase 3 Studies to Evaluate Aducanumab in Patients With Early Alzheimer’s Disease.
    1. He Z, Guo JL, McBride JD, Narasimhan S, Kim H, Changolkar L, Zhang B, Gathagan RJ, Yue C, Dengler C, et al. (2018). Amyloid-beta plaques enhance Alzheimer’s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nature medicine 24, 29–38. - PMC - PubMed

Publication types